Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Estrogens catechol" patented technology

Method for treatment of parkinson's disease

InactiveUS20160022573A1BiocideNervous disorderOral medicationTolcapone
The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.
Owner:NEURODERM

Cephem compound having pseudo-catechol group

A compound of the formula:whereinX is —N═, —CH═, or the like;W is —CH2— or the like;U is —S— or the like;R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like;Q is a single bond or the like;R3 is hydrogen or the like;Ring A is a 6-membered aromatic heterocyclic group having 1-3 nitrogen atoms;each R4 is independently hydrogen, halogen, or the like;m is an integer from 0 to 2;G is —C(═O)— or the like;D is a single bond, —NH—, or the like; andE is a cyclic quaternary ammonium group,or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.
Owner:SHIONOGI & CO LTD

Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders

ActiveUS20090023705A1Eliminate symptomReduces severity of symptomBiocideNervous disorderAdrenergicSleep disorder
The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit / Hyperactivity Disorder (AD / HD).
Owner:CHELSEA THERAPEUTICS

Cephem compound having catechol group

A compound of the formula:whereinX is —N═, —CH═, or the like;W is —CH2— or the like;U is —S— or the like;R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like;R3 is hydrogen or the like;each R4 is independently hydrogen, halogen, or the like;m is an integer from 0 to 2;Q is a single bond, or the like;G is —C(═O)—, or the like;D is a single bond, —NH—, or the like; andE is a cyclic quaternary ammonium group,or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.
Owner:SHIONOGI & CO LTD

Ph-responsive nanoparticle using mussel adhesive protein for drug delivery and method for preparing the same

The present invention relates to a pH-responsive metal-catechol derivative nanoparticle for drug delivery based on a mussel adhesive protein, particularly Fe(III)-DOPA nanoparticle, and a method for preparing the same. A nanoparticle for drug delivery according to the present invention is prepared using a pH responsive substance, catechol derivative-metal complex, particularly Fe(III)-DOPA complex, based on a mussel adhesive protein. Thereby, the present invention has excellent biocompatibility, is capable of easily and quickly penetrating into a target cell, and releases a loaded drug under acidic conditions, which enables to selectively deliver a drug to a specific disease having an acidic environment.
Owner:POSTECH ACAD IND FOUND

Indezole bioisostere replacement of catechol in therafeutically active compounds

The invention discloses a therapeutically active compositions of matter and member species thereof which comprise indazole-containing compounds, said compounds and their therapeutic activity resulting directly from an indazole-for-catechol bioisostere replacement of a catechol-containing compound having the same therapeutic activity, where non-catechol substituents are the same or homologous before and after said replacement, and wherein said compositions of matter comprise a compound of Formula (I<1>) or (I<2>), or a pharmaceutically acceptable salt thereof, wherein in a preferred embodiment R is hydrogen; R is cyclohexyl; and R is ethyl. Ra and Rb are each individually and independently hydrogen or non-catechol substituents of said compounds resulting directly from an indazole-for-catechol bioisotere replacement of said catechol-containing compound having said therapeutic activity, where said non-catechol substituents are the same or homologous before and after said replacement, provided that both of Ra and Rb cannot be hydrogen at the same time. The therapeutic activity involved may comprise cholinesterase inhibitory activity, adrenergic alpha 1-antagonist and beta 1-agonist activity, calcium channel inhibitory activity, antineoplastic activity, and phosphodiesterase type IV inhibitor activity.
Owner:PFIZER PRODS ETAT DE CONNECTICUT

Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders

ActiveUS20130196002A1BiocideNervous disorderDiseaseCatechol-O-methyl transferase
The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.
Owner:MERCK SHARP & DOHME CORP

Pharmaceutical composition containing active ingredient of salvia miltiorrhiza and preparation method and application thereof

The invention discloses a pharmaceutical composition containing an active ingredient of salvia miltiorrhiza and a preparation method and application thereof. The pharmaceutical composition is preparedby compounding the components with the following medicine concentrations: Danshensu (DSS, S) 1.5*10<-4> mol / L, salvianolic acid A (SAA, A) 7*10< 6> mol / L, salvianolic acid B (SAB, B) 3*10 < 4> mol / Land protocatechol (PAL, L) 5*10<-4>mol / L,and the ratio of the four components is S:A:B:L is 150:7:300:500. A modern biology basis of the effects of the salvia miltiorrhiza of promoting blood circulation to remove blood stasis, invigorating pulse and nourishing heart is interpretated for clarifying a material basis and part action mechanism of the salvia miltiorrhiza against cardio-cerebrovasculardisease, an experimental basis is provided for further research and development of new drugs and guidance of clinical application. At the same time, the pharmaceutical composition has a good curativeeffect in treating hypertension.
Owner:HEBEI CHEM & PHARMA COLLEGE

Compositions comprising blockers of L-DOPA renal cell transfer for treatment of Parkinson's disease

A pharmaceutical composition for the treatment of Parkinson's disease comprises L-DOPA and at least one compound capable of blocking the L-DOPA renal cell outward transfer pathway; said blocking compound being chose from (a) a flavonoid phenyl benzopyran derivative; (b) a trans-stilbene derivative; or (c) phloretin [3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone]. The composition may also comprise an inhibitor of the enzyme amino acid decarboxylase (AADC), such a carbidopa or benserazide, and / or an inhibitor of the enzyme catechol-O-methyl transferase (COMT), such as entacapone or tolcapone. The composition is preferably administered in soli form and the L-DOPA may be administered simultaneously or sequentially with the L-DOPA renal cell outward transfer blocking compound.
Owner:波特拉和康潘希亚股份有限公司

Preparation method of thermosensitive hydrogel with adhesiveness and antibacterial activity

InactiveCN108096631AProsthesisProtonationTyrosine
The invention discloses a preparation method of thermosensitive hydrogel with adhesiveness and antibacterial activity. Firstly, natural chitosan is subjected to hydroxybutylation modification to havethermosensitivity (patent number: 201110214776.X); secondly, HBC (hydroxybutyl chitosan) is grafted with L-DOPA (levodopa) with the chemical name of 3-hydroxy-L-tyrosine, and L-DOPA contains catechingroups, so that the hydrogel has good adhesiveness; then, HBC is grafted with EPL (epsilon-poly-L-lysine), EPL is a polypeptide and has the antibacterial efficacy by use of protonated amino groups. The composite gel material has adhesiveness and antibacterial activity and possibly has wide application prospects in the aspects of tissue engineering and skin repairing.
Owner:OCEAN UNIV OF CHINA

Preparation method of norepinephrine bitartrate

The invention relates to the technical field of drug synthesis, and discloses a preparation method of norepinephrine bitartrate, which comprises the following steps of S1, taking chloroacetyl catecholas an initial raw material, carrying out a coupling reaction with dibenzylamine in a reaction solvent to obtain 2-(diphenylmethylamino)-3', 4' dihydroxyacetophenone hydrochloride, S2, carrying out hydrogenation catalysis on the 2-(diphenylmethylamino)-3', 4' dihydroxyacetophenone hydrochloride to reduce in the solvent to obtain racemic norepinephrine, S3, enabling racemic norepinephrine to be subjected to D-tartaric acid resolution in an alcohol-water solution, and acquiring L-norepinephrine D-tartrate, and S4, neutralizing the L-norepinephrine D-tartrate in water by alkali to obtain L-norepinephrine. Compared with the existing preparation method, the preparation method disclosed by the invention has the advantages that easily available starting materials are used, good reproducibility ofa synthetic route is ensured, unit operation is simple, economic accounting is realized, each step of reaction is easy to purify, the quality is controllable, and the reaction yield is greatly improved.
Owner:合肥亿帆生物制药有限公司

Bleed-free injection needle coated with crosslinked chitosan having introduced catechol group and oxidized catechol group

The present invention relates to a bleed-free injection needle coated with crosslinked chitosan having an introduced catechol group and oxidized catechol group, and the bleed-free injection needle according to the present invention is advantageous in that said needle can suppress the bleeding that occurs during an injection and hence can beneficially be used not only in patients having reduced hemostatic capacity such as diabetic patients, anticancer therapy patients and haemophilia patients but also in patients exhibiting blood rejection reactions and in injections to children as well.
Owner:INNO THERAPY INC

Method for quantitative determination of catechol-o-methyl transferase activity and use thereof

The invention discloses a method for quantitative determination of catechol-o-methyl transferase activity and a use thereof and belongs to the technical field of biological medicines. The method utilizes 4-acetoxy-7,8-dihydroxycoumarin as a COMT enzyme specific probe substrate. The substrate can be specifically catalyzed through the COMT enzyme to produce a 8-methoxy product, the 8-methoxy product can produce a fluorescence signal at wavelength of 520nm and through detection of fluorescence intensity change, COMT activity is detected quantificationally. The method can be used for quantitative evaluation of activity of COMT enzymes in biological samples with different sources and can also be used for external rapid screening of COMT inhibitors and assessment of an inhibition capability. The method can be used for quantitative assessment of real activity of COMT enzymes in various external biological samples, realizes inhibitor rapid screening and inhibition capability quantitative evaluation and can be used for evaluating catalytic activity of different types of COMTs and COMT mutants with different amino acid sequences and further evaluating a catechol drug metabolism capability. The method has the advantages of high selectivity, low price, acquisition easiness and high sensitivity.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI

Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition

InactiveUS20100280083A1Potent COMT inhibitory activityImprove bioavailabilityBiocideNervous disorderHydrogenAcyl group
The present invention provides compounds represented by general formula (I):or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is halo-lower alkyl, lower acyl, halo-lower alkylcarbonyl, cycloalkylcarbonyl, optionally substituted arylcarbonyl, lower alkoxycarbonyl or the like; R4 is lower alkyl, halo-lower alkyl, cycloalkyl, lower alkoxy-lower alkyl or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.
Owner:KISSEI PHARMA

Application of oroxylin A and pro-drug thereof as catechol-type medicine synergist

An application of oroxylin A and a pro-drug thereof as a catechol-type medicine synergist belongs to the technical field of medicines. The compound is used as the catechol-type medicine synergist and has the following structure general formula (I), wherein R is hydrogen, carboxylic ester, glucuronic acid and the like substitutive groups. One or more compounds of the oroxylin A and the pro-drug thereof can be mixed with levodopa according to a certain ratio to prepare a drug composition for treatment of Parkinson's disease. The oroxylin A and the pro-drug prepared through modification thereof are improved in both solubility and transmembrane capability and are significantly prolonged in in-vivo metabolic half life period, which is longer than the in-vivo metabolic half life periods of majority of catechol-type medicines, so that the compounds have excellent medicine preparation prospect. In addition, the compounds also can be combined with a catechol-type medicine to form a compound medicine. The compound medicine can be prepared into an oral-taking slow-release preparation to further improve oral-taking bioavailability and treatment effects of the catechol-type medicines.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI

Nitric oxide in-situ hydrogel for treating colitis

ActiveCN111956600AEasy to useRealize the purpose of positioning and long-term treatmentAntipyreticInorganic active ingredientsNitric oxide gasEstrogens catechol
The invention relates to nitric oxide in-situ hydrogel for treating colitis. The hydrogel comprises a hydrogel matrix and nitric oxide nanobubbles, and the nitric oxide nanobubbles are uniformly dispersed in the hydrogel matrix. The hydrogel matrix consists of a catechol-terminated polyoxyethylene-polyoxypropylene-polyoxyethylene copolymer, heparin-poloxamer and an epidermal cell growth factor, wherein the mass ratio of the catechol-terminated polyoxyethylene-polyoxypropylene-polyoxyethylene copolymer to the heparin-poloxamer is (1-5):10, and the molar mass of the epidermal growth factor is equal to the molar mass of the 50% heparin-poloxamer. The nitric oxide nanobubbles are composed of vesicles formed by wrapping nitric oxide gas with egg yolk phospholipid and poloxamer as bubble film materials, the mass ratio of the egg yolk phospholipid to the poloxamer is 1:25, the particle size range is 500-900 nm, and the concentration is 6 x 10<7> to 9 x 10<7> / mL. The nitric oxide in-situ hydrogel disclosed by the invention is perfused to a colon part and is used for treating colitis.
Owner:WENZHOU MEDICAL UNIV

Chitosan dressing for control of bleeding in transurethral prostatectomy

PendingUS20210059868A1Faster control of bleedingHigh cure rateNon-adhesive dressingsSwabsTransurethral prostatectomyEstrogens catechol
The present invention relates to a biocompatible, foldable, thin profile, low mass and high surface area, chitosan dressing, optionally modified with catechol, and suitable for treating bleeding in a physiological environment, e.g. bladder, and in particular in connection with the TURP procedure. The characteristics and structures of the chitosan dressing are provided. Methods of making and using the chitosan dressing are also provided.
Owner:TRICOL BIOMEDICAL INC

Reagent and test strip for diagnosing bovine subclinical mastitis and preparation method thereof

The invention discloses a reagent and a test strip for diagnosing bovine subclinical mastitis and a preparation method thereof. The reagent comprises the following components: catechol violet, neutral red, litmus, Nile blue A and alpha-naphtholbenzein. The invention further discloses a diagnostic test strip prepared from the reagent for diagnosing bovine subclinical mastitis and a usage method thereof. The diagnostic test strip provided by the invention has advantages of low cost, convenient usage and high diagnostic accuracy. Clinical diagnostic test results show that the test paper provided by the invention has an accuracy rate higher than 95% on detecting bovine subclinical mastitis, and can be applied to clinical detection of bovine subclinical mastitis.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Nitric oxide in-situ hydrogel for treating osteoarthritis

ActiveCN111973550AMeet the needs of controlled release long-acting therapyEasy to usePeptide/protein ingredientsAntipyreticArticular cavityNitric oxide gas
The invention provides a nitric oxide in-situ hydrogel for treating osteoarthritis. The nitric oxide in-situ hydrogel comprises a hydrogel matrix and nitric oxide nanobubbles, wherein the nitric oxidenanobubbles are uniformly dispersed into the hydrogel matrix. The hydrogel matrix is composed of a catechole-terminated polyoxyethylene-polyoxyepropylene-polyoxyethylene copolymer, heparin-poloxamerand an acidic fibroblast growth factor; the mass ratio of the catechole-terminated polyoxyethylene-polyoxyepropylene-polyoxyethylene copolymer to the heparin-poloxamer is (1-5):10; and the molar massof the acidic fibroblast growth factor is equal to that of the heparin-poloxamer. The nitric oxide nanobubbles are composed of vesicles formed by wrapping a nitric oxide gas with egg yolk lecithin andpoloxamer as bubble film materials; the mass ratio of the egg yolk lecithin to the poloxamer is 1:25; the particle size range is 500-900 nm; and the concentration is 1*10<7> / mL to 5*10<7> / mL. The nitric oxide in-situ hydrogel provided by the invention is injected into an articular cavity for treating the osteoarthritis.
Owner:WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products